Home

Spreekwoord Incarijk eigenaar rituximab dose rheumatoid arthritis Toerist impliciet roekeloos

Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens | HTML | Acta Dermato-Venereologica
Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens | HTML | Acta Dermato-Venereologica

Rituximab Biosimilar Truxima Now Available for Rheumatoid Arthritis - MPR
Rituximab Biosimilar Truxima Now Available for Rheumatoid Arthritis - MPR

Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology

Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study - Consumer Health News | HealthDay
Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study - Consumer Health News | HealthDay

Rituximab Infusion Dosing | RIABNI™ (rituximab-arrx)
Rituximab Infusion Dosing | RIABNI™ (rituximab-arrx)

RITUXAN Dosage & Rx Info | Uses, Side Effects
RITUXAN Dosage & Rx Info | Uses, Side Effects

PV | RITUXAN® (rituximab) Dosing & Infusion Resources
PV | RITUXAN® (rituximab) Dosing & Infusion Resources

Should You Get the COVID-19 Vaccine If You Take Rituximab?
Should You Get the COVID-19 Vaccine If You Take Rituximab?

RA | RITUXAN® (rituximab) Dosing Overview for Rheumatoid Arthritis
RA | RITUXAN® (rituximab) Dosing Overview for Rheumatoid Arthritis

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating

Rituximab protocols | Download Table
Rituximab protocols | Download Table

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine

ePosters - A retrospective audit of reduced-dose rituximab in rheumatoid arthritis
ePosters - A retrospective audit of reduced-dose rituximab in rheumatoid arthritis

VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression | 2 Minute Medicine
VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression | 2 Minute Medicine

PV | Taking & Dosing RITUXAN® (rituximab)
PV | Taking & Dosing RITUXAN® (rituximab)

Ultra-Low Rituximab Dose in RA Fails to Meet Non-Inferiority
Ultra-Low Rituximab Dose in RA Fails to Meet Non-Inferiority

Rituxan (Rituximab): Uses, Dosage, Side Effects, Interactions, Warning
Rituxan (Rituximab): Uses, Dosage, Side Effects, Interactions, Warning

Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis | NEJM
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis | NEJM

European Medicines Agency approved rituximab dosing regimens [ 10 ] . | Download Table
European Medicines Agency approved rituximab dosing regimens [ 10 ] . | Download Table

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study | BMC Musculoskeletal Disorders | Full Text
Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study | BMC Musculoskeletal Disorders | Full Text

Protocol of rituximab dosing and administration. | Download Scientific Diagram
Protocol of rituximab dosing and administration. | Download Scientific Diagram

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis | SpringerLink
Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis | SpringerLink

JCM | Free Full-Text | Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)
JCM | Free Full-Text | Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)